



100% research since 1945

2017 Operating Grants Competition Results

The Cancer Research Society's Board of Directors approved a budget of **\$8.4 million** for **70** new projects:


- 42 funded by the Cancer Research Society
- 28 funded in partnership with different organizations or families

→ Overall Success Rate*: 15.5%



- ✦ Men: 15.3%
- ✦ Women: 15.9%
- ✦ Young Investigators: 19.0%
- ✦ New Applications: 13.8%
- ✦ Renewals: 44.0%



The financial support granted by the **Cancer Research Society** is made possible thanks to the generosity of our donors and partners. *We know that we can count on your support in our future fundraising campaigns!*

Grants Awarded by Province



*not considering withdrawn applications

Researcher	Project Title	Funding Details
<i>Alain, Tommy</i> CHEO Research Institute	Characterization of a new pharmaco-viral approach for the treatment of brain cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Allan, Alison</i> University of Western Ontario	Molecular and disease stage determinants of pre-metastatic niche formation during breast cancer metastasis to the lung	\$ 120,000/ 2 years
<i>Archambault, Vincent</i> Institute for Research in Immunology and Cancer	Targeting the cell cycle kinase Wee1 in cancer: towards mechanism-based improvements	\$ 120,000/ 2 years
<i>Asfaha, Samuel</i> University of Western Ontario	<i>In vivo</i> targeting of cancer stem cells in colon cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 

Researcher	Project Title	Funding Details
<i>Baker, Kristi</i> University of Alberta	Inducing anti-tumour immunity against colorectal cancer using exosome-Ig immune complexes	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  Canadian Institutes of Health Research / Instituts de recherche en santé du Canada
<i>Berman, David M.</i> Queen's University	Proteomic biomarkers of urothelial stroma controlling cancer invasion and progression	\$ 120,000/ 2 years <i>Funded in partnership with Bladder Cancer Canada</i>  BLADDER CANCER CANADA / CANCER DE LA VESSIE CANADA
<i>Bhatia, Mick</i> McMaster University	Targeting GHSR in human acute myeloid leukemic stem cells	\$ 120,000/ 2 years
<i>Boisvert, Francois-Michel</i> Université de Sherbrooke	Ubiquitination of the MCM-ASF1 complex by DDB1-CUL4 following DNA damage	\$ 120,000/ 2 years

Researcher	Project Title	Funding Details
<i>Bouchard, Michel</i> McGill University	Apoptosis resistance of prostate cancer stem cells	\$ 120,000/ 2 years
<i>Brand, Marjorie</i> Ottawa Hospital Research Institute	Targeted proteomic analysis of epigenetic factors in leukemia	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa and the Ottawa Hospital Research Institute</i>
<i>Bremner, Rod</i> Lunenfeld Tanenbaum Research Institute, Sinai Health Services	MYCN, lineage, and cancer initiation	\$ 120,000/ 2 years
<i>Burke, John</i> University of Victoria	Defining the molecular mechanism of oncogenic Ras activation of phosphoinositide 3-kinases	\$ 120,000/ 2 years






uOttawa





Ottawa Hospital
Research Institute
Institut de recherche
de l'Hôpital d'Ottawa

Researcher	Project Title	Funding Details
Campos, Eric The Hospital for Sick Children	Safeguarding genomic integrity at replication forks by the TONSL-MMS22L histone chaperone	\$ 120,000/ 2 years
Chang, Hong University Health Network	Role of MARCKS in multiple myeloma drug resistance	\$ 120,000/ 2 years <i>Funded in partnership with Myeloma Canada</i>
Christian, Sherri Memorial University of Newfoundland	Identification of adipocyte-derived modulators of breast cancer progression	\$ 120,000/ 2 years
Coppolino, Marc University of Guelph	Preventing breast cancer metastasis by blocking MT1-MMP trafficking	\$ 119,640/ 2 years



Researcher	Project Title	Funding Details
Côté, Jocelyn University of Ottawa	The role of Protein Arginine Methyltransferase 7 (PRMT7) in breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with CURE Foundation</i> 
Cowan, Kyle CHEO Research Institute	Pannexin 1 channels as a new therapeutic target for neuroblastoma	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa, the Children's Hospital of Eastern Ontario</i>  
Dagnino, Lina University of Western Ontario	Role of FER kinase in melanoma metastasis	\$ 119,940/ 2 years

Researcher	Project Title	Funding Details
<i>Eaves, Connie</i> BC Cancer Agency	Role of autophagy in a de novo model of human breast cancer genesis from purified primary normal cells	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Gervais, Thomas</i> École Polytechnique de Montréal	Lab-on-a-chip solutions to expand the scope of tissue microarrays to the study of tissue response to drugs	\$ 120,000/ 2 years
<i>Gratton, Jean-Philippe</i> Université de Montréal	Understanding the role of ZO-1 in endothelial cell junctions and in tumour progression	\$ 120,000/ 2 years
<i>Gratton, Jean-Philippe</i> Université de Montréal	Role and regulation of PAK2 in endothelial cells and in tumour angiogenesis	\$ 120,000/ 2 years
<i>Guimond, Martin</i> Centre de recherche de l'hôpital Maisonneuve-Rosemont	The effect of graft-versus-host-disease on the peripheral niche controlling the regeneration of naïve CD8 T cells after allogeneic stem cell transplantation	\$ 120,000/ 2 years

Researcher	Project Title	Funding Details
<i>Ismail, Ismail</i> University of Alberta	Targeting DNA repair pathways for multiple myeloma treatment	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  Canadian Institutes of Health Research / Instituts de recherche en santé du Canada
<i>Jasmin, Bernard</i> University of Ottawa	Defining the novel roles of Staufen1 in rhabdomyosarcoma and its therapeutic potential	\$ 120,000/ 2 years
<i>Jean, Steve</i> Université de Sherbrooke	Signalling functions in cancer for a RAB GTPase	\$ 120,000/ 2 years
<i>Jeannotte, Lucie</i> Université Laval, CRCHU de Québec	Characterization of the role of the Yin Yang1 (YY1) transcription factor in pleuropulmonary blastoma	\$ 120,000/ 2 years
<i>Johnson, Pauline</i> University of British Columbia	To evaluate chondroitin sulfate as a regulator of cell adhesion and tumour metastasis	\$ 120,000/ 2 years

Researcher	Project Title	Funding Details
<i>Krajinovic, Maja</i> CHU Sainte-Justine, Université de Montréal	Pharmacogenetics markers for treatment individualization in childhood patients with acute lymphoblastic leukemia	\$ 119,075/ 2 years
<i>Krawczyk, Connie</i> Goodman Cancer Research Centre, McGill University	A dual role for PD-L1 expression on dendritic cells and the consequences for anti-tumour immunity	\$ 120,000/ 2 years
<i>Larrivée, Bruno</i> Université de Montréal	Normalization of tumour vessels to promote anti-tumour T-cell responses	\$ 120,000/ 2 years
<i>Lee, Cheng-Han</i> BC Cancer Agency	Targeting genomic aberrations in malignant mixed Mullerian tumours (carcinosarcoma)	\$ 120,000/ 2 years <i>Funded in partnership with the Ann Matyas Memorial Fund</i>
<i>Lesage, Sylvie</i> Hôpital Maisonneuve- Rosemont	Defining the tumoricidal pre-mNK cell human equivalent	\$ 120,000/ 2 years







Ann Matyas
Memorial Fund

Researcher	Project Title	Funding Details
Luyt, Leonard University of Western Ontario	Targeting enhancer of Zeste 2 (EZH2) for non-invasive cancer imaging	\$ 120,000/ 2 years
Mahoney, Douglas University of Calgary	Smac mimetic compounds as a cancer immunotherapy	\$ 120,000/ 2 years
Mallette, Frédérick Antoine Centre de Recherche de l'Hôpital Maisonneuve-Rosemont / Université de Montréal	The role of cholesterol metabolism in cellular senescence and liver cancer	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>
Marcato, Paola Dalhousie University	Identification of novel hypermethylated tumour suppressor genes important in breast cancer progression and treatment response	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>

Environment-Cancer Fund™






Researcher	Project Title	Funding Details
Marsolais, David Université Laval	Identification of dysregulated sphingolipids in lung cancer	\$119,899/ 2 years
McGlade, Jane The Hospital for Sick Children and the University of Toronto	Approaches to regulate Cbl ubiquitin ligase activity and control oncogenic signalling in leukemia	\$ 120,000/ 2 years
McKenna, Sean University of Manitoba	Investigating the regulatory role of an RNA-quadruplex helicase on oncogenic transformation	\$ 119,140/ 2 years
Melichar, Heather Centre de Recherche-Hôpital Maisonneuve-Rosemont / Université de Montréal	Optimizing the effector T-cell response for improved adoptive cell therapy against cancer	\$ 120,000/ 2 years
Michalak, Thomas I. Memorial University	Mechanism of initial hepatitis B virus (HBV)-host genome integration in human hepatocytes and in the woodchuck model of HBV-associated hepatocellular carcinoma	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  



Researcher	Project Title	Funding Details
Nachtigal, Mark CancerCare Manitoba	Investigating mechanisms of chromosomal instability in human ovarian cancer	\$ 120,000/ 2 years
Nepveu, Alain McGill University	Effects of DNA pol β modulation on the response to treatments	\$ 120,000/ 2 years
Panasci, Lawrence Jewish General Hospital, Lady Davis Institute for Medical Research	PARP3 inhibitors to improve the treatment of metastatic breast cancer	\$ 119,000/ 2 years <i>Funded in partnership with the Breast Cancer Society Of Canada</i>  BREAST CANCER SOCIETY <i>of Canada</i> [™] LA SOCIÉTÉ DU CANCER DU SEIN <i>du Canada</i> [™]
Petrik, Jim University of Guelph	Vascular normalization as a mechanism to increase uptake and efficacy of oncolytic viruses and vaccine-induced effector cells for the treatment of advanced stage ovarian cancer	\$ 120,000/ 2 years <i>Funded in partnership with Ovarian Cancer Canada</i>  Ovarian Cancer Canada Cancer de l'ovaire Canada





Researcher	Project Title	Funding Details
<i>Postovit, Lynne-Marie</i> University of Alberta	Linking inactivating mutations in chromatin remodeling complex subunits to aggressive dedifferentiated endometrial carcinoma	\$ 120,000/ 2 years
<i>Reyes-Moreno, Carlos</i> Université du Québec à Trois-Rivières	Therapeutic targeting of mediators and inflammation pathways associated with bladder cancer progression and metastasis	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>
<i>Riazalhosseini, Yasser</i> McGill University	KDM5C mutations as determinants of sex-dependent therapy in renal cell carcinoma	\$ 120,000/ 2 years
<i>Rodier, Francis</i> Université de Montréal, CRCHUM	Real-time evaluation and enhancement of therapy-induced senescence using in vivo and ex vivo human ovarian cancer tissues	\$ 120,000/ 2 years



Researcher	Project Title	Funding Details
Rosen, Kirill Dalhousie University	Autophagy mediator Atg12 as an inhibitor of ras oncogene-driven tumorigenesis	\$ 120,000/ 2 years <i>Funded in partnership with The Beatrice Hunter Cancer Research Institute</i>  BEATRICE HUNTER Cancer Research Institute Evolving Cancer Research in Atlantic Canada
Russell, Ryan University of Ottawa	Characterization of VHL-mediated RB regulation in renal cancer	\$ 120,000/ 2 years
Sabourin, Luc Ottawa Hospital Research Institute	Acquired Periostin gene expression in breast cancer invasion and metastasis	\$ 120,000/ 2 years <i>Funded in partnership with CURE Foundation</i>  FONDATION CURE FOUNDATION cancer du sein breast cancer
Sabri, Siham The Research Institute of the McGill University Health Centre	Characterization of the immunosuppressive local microenvironment and therapeutic targets in glioblastoma	\$ 120,000/ 2 years

Researcher	Project Title	Funding Details
<i>Shepherd, Trevor</i> University of Western Ontario	Overcoming chemotherapy resistance by autophagy inhibition in metastatic ovarian cancer	\$ 118,180/ 2 years <i>Funded in partnership with Ovarian Cancer Canada</i>  Ovarian Cancer Canada Cancer de l'ovaire Canada
<i>Shmulevitz, Maya</i> University of Alberta	Exploring and exploiting proteases in breast cancer microenvironments to enhance the potency of reovirus oncolysis	\$ 120,000/ 2 years
<i>Spagnuolo, Paul</i> University of Guelph	Drug-induced inhibition of beta-oxidation in acute myeloid leukemia	\$ 120,000/ 2 years
<i>Stagg, John</i> Université de Montréal, CRHUM	Eosinophils in cancer immunotherapy: friends or foes?	\$ 120,000/ 2 years

Researcher	Project Title	Funding Details
<i>Suh, Woong-Kyung</i> Montreal Clinical Research Institute	Role of Bcl6 in disease progression of AITL, a germinal center-derived T-cell lymphoma	\$ 120,000/ 2 years <i>Funded in partnership with the Daniel Primeau Research Fund</i>  Daniel Primeau Research Fund
<i>Tang, Damu</i> McMaster University	Characterization of CYB5D2-mediated suppression of clear cell renal cell carcinoma (ccRCC)	\$ 120,000/ 2 years
<i>Taubert, Stefan</i> The University of British Columbia	Exploring Mediator-dependent stress resistance as a new target in cancer	\$ 120,000/ 2 years
<i>Trudel, Dominique</i> Université de Montréal	Effects of the leucocytic infiltration of intraductal carcinoma of the prostate	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 

Researcher	Project Title	Funding Details
Turley, Eva Lawson Health Research Institute	Mechanisms of hyaluronan-mediated resistance to UVB-induced keratinocyte tumours	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  
Vizeacoumar, Franco Saskatchewan Cancer Agency, University of Saskatchewan	Polokinase and drug resistance in pancreatic cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>  Charlotte Légaré Memorial Fund
Waisman, David Dalhousie University	The role of the plasminogen receptor p11 in the malignancy of lung cancer	\$ 120,000/ 2 years
Wallace, Valerie Krembil Research Institute, UHN	Norrin/Frizzled4 stromal signaling and medulloblastoma progression	\$ 120,000/ 2 years <i>Funded in partnership with the C¹⁷ Council</i>  Children's Cancer & Blood Disorders

Researcher	Project Title	Funding Details
<i>Wurtele, Hugo</i> Centre de recherche de l'Hôpital Maisonneuve- Rosemont	DNA replication stress: a novel determinant of DNA repair capacity in melanoma	\$ 120,000/ 2 years
<i>Yang, Xiang-Jiao</i> McGill University	Roles of the MEF2B transcription factor in development of B-cell lymphoma	\$ 120,000/ 2 years
<i>Zogopoulos, George</i> Research Institute of the McGill University Health Centre	Elucidating the genetics of pancreatic cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>



Charlotte Légaré
Memorial Fund